Company Registration Number: 60210831En8land and Wales)
Charity registration number- 1118829
INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER
RESPIRATORY VIRUS DISEASES
la company Ilmlted by guarantee)
REPORT OFTHE TRUSTEES AND FINANCIAL
STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
'ADiUY68Q'
2711212024
COMPANIES HOUSE
A8
#204 1
Registered Address:
54A Castle Road.
Isleworth. Middlesex.
TW7 6QS

CONTENTS
PAGE
REPORT OF THE TRUSTEES
STATEMENT OF THE TRUSTEES, RESPONSIBILITIES
12
INDEPENDENT AUDITOR'S REPORT
14
STATEMENT OF FINANCIAL ACTIVITIES
19
BALANCE SHEET
20
STATEMENT OF CASH FLOWS
21
NOTES TO THE FINANCIAL STATEMENTS
22

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
The trustees, who are also directors of the charitable company for the purposes of the Companies Act 2006,
present their report and financial statements of the charitable company for the year to 31st March 2024
and confirm they comply with the requirements of the Companies Act 2006, Charities Act 2011 and the
Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities
preparing their accounts in accordance with the Financial Reportin8 Standard applicable in the UK and
Republic of Ireland (Charities SORP IFRS 1021).
REFERENCE AND ADMINISTRATIVE DETAILS
Reglstered Company number: 6021083 (England and Wales).
Reglstered Charlty number: 1118829
Re81stered offlce: 54A Castle Road, Isleworth, LONDON TW7 6QS
TRUSTEES IN THE PERIOD APRIL 2023 TO MARCH 2024 AND UP TO THE DATE OF SIGNING OF THESE
ACCOUNTS:
Rebbeca COX, Deputy Chair
Alan HAY. Treasurer {ex-officio}
Frederlck G HAYDEN, Deputy Chalr (appointed 11 January 2024)
Jackie KATZ (resigned 26 October 2023)
Ultan POWER, Deputy Chair (oppointed I l January 2024)
John M Wood (resigned 26 October 2023)
Marla ZAMBON, Cha5r

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
STRucfuRE, GOVERNANCE AND MANAGEMENT
Governing Document
The charitable company is governed by its Memorandum and Articles of Association of 6 December 2006 as
amended by the special resolution dated 14 February 2007 and the amendments of Articles dated 5
September 2010, 11 September 2017, 6 September 2018, 29 August 2019 and 11 November 2020.
Recruitment and Appolntment of New Trustees
According to the Articles of Association of the charitable company, the number of trustees shall be not less
than five. After each AGM one-third of the trustees who are subject to retirement by rotation shall retire
from office, although they can be re-appolnted. The trustees may appoint a person who is willing to act to
be a trustee either to fill a vacancy or as an additional trustee for specific purposes agreed by the Council.
With the intention of achieving both a full global balance and representation of researchers at all career
stage5 on the Council, each year there is a call for new members that are not represented.
Annual General Meeting
The 17th AGM was held via video call on 26 October 2023. During the meeting Rebecca Cox {Norwavl,
Maria Zambon IUKI, Sook-san Wong (Hong Kongl, Nelson Lee {Canadal, John Mccauley IUKI, Jude Jayamaha (Sri
Lankal and Norio Sugaya {Japan} were re-appointed to Council, and Erik Karlsson {Cambodial and Ultan Power
(Northern Ireland, UK) were appointed as new members of Council. Formal thanks for many years, service were
given to Jackie Katz {USAI and John Wood IUKI who completed their terms as Trustees at the AGM.
Governance
Ih
The Society's Articles of Association were amended followlng the 14 AGM In 2020, During the period
covered by this annual report, the society operated following a cadence of meeting5 involvin8 the
Trustees, the Executive Committee and Council. The Executive Committee is comprised of the Directors
and Trustees of the Society, and the Chairs of the Societvs Special Interest groups. Council is comprised of
the Executive Committee and members of Council elected by the ISIRV membership.
Durin8 the year the Trustees have been Involved in extensive discussions regarding the operational
structure of the Society, assurance and compllance processes. Followin8 a strategy away day in Valencia in
September 2023. the bu51ness of the Executive Committee has focused on the operational, financial and
strategic direction of the Society. The business of the Council has been reviewed and revised as part of the
ISIRV strategy for 2024-2026 and the delivery of activitie5 underpinning the strategy.
Objectives and Aims
The objects of the charitable company are the relief of slckness and the preservation and protection of
health by promoting the prevention, detection, treatment and control of influenza and other respiratory
virus diseases throughout the world.
The aims of the charitable companyare generally achieved by the sharing of information and stimulating
interaction between researchers and others regarding influenza and other respiratory virus disease5
through a scientific journal. a website, and scientific conferences including the Society's flagship congress,
Options for the Control of Influen2a, and a variety of other Special Interest Group1SIGI conferences and
activities dependent on specialist knowledge. In recent years the Society has developed an increasing

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
breadth of focus, with the School of Influenza being expanded to include other respiratory viruses, event
planning for International Meetings on Respiratory Pathogens IIMRPI and the inclusion prominence of the
International Respiratory Syncytial Virus Society IIRSVS) as a SIG with RSV conferences planned every 2
years. A rolling programme of events is essential to meeting the 5ocietrfs objectives. whereby scientists
and clinicians can share the latest research and clinical applications in the treatment and prevention of
influenza and other respiratory virus diseases and to raise awareness amon8 policy-makers.
Another of ISIRV'S charitable aims is to provide financial support to enable early career scientists and
scientists from developing countries to attend ISIRV meetings and other respiratory virus-related
conferences, who otherwise tould not afford to do so. The Society continues to look at ways to intrease this
type of support, including recognition awards for early career scientists and setting up designated funds for
this purpose. During September 2023, Council attention was given to revising our S-year strategic plan for
the Society to include the elements discussed above. help guide the development and growth of the Society
and provide a focus for prioritisation of activities over the next 3 years. Partnership development and
collaboration with other professional societies and groups was considered an important area to develop
further and is reflected in some of the activities over the course of 2023124. Virtual educational webinars.
currently 6 per year, are now firmly part of ISIRV'S future operating model, noting that hybrid solutions may
reach a more diverse audience than before.
Publlc benefit Statement
ISIRV'S charitable purposes are to facllltate the relief of sickness and the preservation of health bv
promoting the prevention. detection, treatment and control of Inf luenza and other respiratory virus
diseases throughout the world. From April 2023 to March 2024 the Society has carried out its objectives bv
convening conferences and schools, hosting webinars free to all, and the publication of its society journal
Influen20 ond Other Respirotory Viruses, alongside the provision of grants and bursaries for attendance at
ISIRV events. The Trustees of ISIRV confirm they have given regard to the Charity Commission's public
benefit guidance when planning its activities and when preparing this report.
Overvlew of April 202>March 2024
8etween Aprll 2023 and March 2024, In a return to normality post pandemic, influenza and other respiratory
virus actlvlty fluctuated globally, with seasonal outbreaks returning towards pre-pandemic levels. Regions in the
Northern Hemisphere, particularly North America and Europe. experienced typical influenza seasons, now with
co-circulation of SARS Cov-2 which has become another circulating respiratory virus, endemic in the human
population, putting additional strain on healthcare systems. In the Southern Hemisphere. influenza cases were
comparable to previous years.
New seasonal and zoonotic influenza strains also emerged,avian HSNI influenza virus has caused massive
mortality among poultry and in some species of wild birds and marine mammals across the globe. One strain
(83.13) of avian influenza clade 2.3.4.4b has spread widely in dairy cattle in the USA with associated spillover
human infections, posing an unanticipated threat to human and veterinary sector, once again emphasisin8 the
ever present pandemic threat posed by influenza A. Overall, 2023-2024 emphasized the need for ongoing
surveillance, Improved glob31 vaccination coverage, and adaptable public health strategies to manage
respiratory viruses, especially in vulnerable populations. Efforts are now focused on strengthening pandemic
preparedness and seasonal vaccination campaigns worldwide. noting the necessity for vaccine updates for
SARS-CoV-2 as an addition to the global public health agenda. All of these natural events, and consequent
impacts on scientific work, healthcare and human societies shape the activities and direction of the society

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
Events
April 2023-March 2024
As we entered the period of this report, we left behind the tumultuous years of the COVID-19 pandemic
following WHO'S declaration on S May 2023 that the global health emer8ency was over. This created the
opportunity for reflection and celebration of scientific developments and contributions from ISIRV
members via a return to face to face and hybrid events.
Advancing Respiratory Virus Therapeutics: Lessons Learned from cov1￿19
th
The 7 AVG Conference Antiviral was hosted by the AVG ISIRV SIG In May 2023 In Seattle, USA. The event
was a resounding success (attracting almost 200 attendees) and brought tO8ether local US expertise and
81obal perspectives on advantes in the development of antiviral and other therapeutics for respiratory
virus infections and the therapeutics to reflect on the lessons from the pandemic.
Topics included Iprelcllnlcal development, utilisation of existing therapeutics, regulation for new drugs,
surveillance including antiviral resistance, sequencing, and implementation. The event culminated with a very
lively discussion around scientific misinformation and how this can be handled. Three domestic and two
International travel grants were awarded.
Weblnar serles
Andres Pizzorno from the International Center for Research in Infectious Diseases in Lyon, France, has overseen
the ISIRV webinar series since 2022.
Durlng the year the following webinars took place:
The
resent and future of treatment-oriented surveill
nce- Jun
202
Winter lannin
and influenza with the Healthcare Infection Societ Se
tember 2023
Challen
e5 and
romise of clinical trials for res
irato
antivirals - Ortober 2023
RSV vaccination in the elderl
ulation - Janua
2024
Emer
Influenza threats and the human-animal interface- March 2024
The webinar series, whlch Is freely available, was attended cumulatlvely by several thousand resplratory
virus scientists from across the globe. Recordings are available on demand via the links above.
Organlsatlonal Strategy
In July 2023 the Society engaged a consultant to work with the Executive Committee and Council to review and
strengthen the Society's governance structure and processes. and to work with the Executive Committee and
Council to review exi51tin8 Strate8V.
During a focussed strategy away day session in Valencia in September 2023. it was agreed:
l. The mission of society remained constant:
ISIRV should maintain independence and scientific excellence
The scope needs to broaden to give emphasis to other respiratory viruses
A minor name change for the Society will be proposed

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
2. We anticipate growth of the Society..
Which required urgent investment in society infrastructure and business support
Greater support for the financial management
3. We need plans for governance, leadership renewal and support of SIGS
4. There need5 to be 5eriou5 investment to enhance visibility and communications capabilitv
Following the September meetin8, the Society began to deliver its revised strategy in earnest, and has enga8ed
two consultants to strengthen its finance and communications operations.
Journal: Influenza and Other Resplratory Vlruses
Influenza and Other Respirotory Viruses IIORVI, the official journal of ISIRV, is an Open Access journal. It 15
the first journal to specialise exclusively on influenza and other respiratory viruses and strives to play a
key role in the dissemination of information in this broad and challenging field. It is aimed at laboratory
and clinical scientists, public health professionals, and others around the world involved in a broad range
of activities in this field. The journal is wholly owned and published by Wiley and provides a modest
royalty stream to the Society.
The journal has seen a steady rise In Impact factor Since 2016 to a high of 5.6112021 Impact Factor). As
anticipated, the 2023 Impact Factor (released in July 20241 fell slightly from 4.4 to 4.3 as the publlcatlons
relating to COVID-19 dropped out of the citation window timeframe. The Editorial 8oard is comprised of 30
international editors, Dr Ben Cowling as Editor-in- Chief and Senior Editors Drs Alan Hampson, Rebecca Cox
and Calum Semple who facilitated the publication of 138 articles during 202312022..1201. The total
number of submissions in 2023 increased (30.4%} compared with 2022. This compares with an increase
18.5%) across all Wiley journals in the Infectious Disease and Microbiology subject area. Desplte the sli8ht
decrease in the 2023 Impact Factor, the journal rankings have improved to 11/41 in Virology {Q21 and
261132 in Infectious Diseases (Qll - up from Virology 17/36 {20221 and Infectious Diseases 4019612022).
Partnershlps
One of the area5 of development for the society, hlghlighted In Its 5-year strate8ic plan, are the
opportunities afforded by partnerships wlth other professional sclentlflc organisations and societies with
similar interests. Progress has been made in this area through the partnership with European Societ for
Clinical Microbiology and InfectlQUs Di5ea5es IESCMIDI and hosting of focused ISIRV symposia in the huge
ECCMID annual conference during April 2023 in Copenhagen and in ESCMID Global in April 2024 In
Barcelona. In addition, during the year ISIRV also ran a joint webinar on the tDPiC of Infection Prevention
and Control IIPC) challenge5 and solutions webinar - Winter planning and influenza with the Healthcare
Infection Society. A mini isirv symposium on the topic of genomic surveillance was hosted at ESWI
meetin8 in Valencia October 2023.
Ourin8 2023, ISIRV took part in discussions with R
VINET in order to establish a shared set of principles for the
forward planning of scheduling for major international RSV meetlngs hosted by ISIRV and the Internatlonal
Respiratory Syncytial Virus Society liRSVs, a special interest group of ISIRV} and ReSViNET. It was agreed that the
organisations would run their respective meetings focused on RSV during alternate years. Both organisations
agreed there was a mutual benefit to be gained from such an agreement to benefit our shared scientific
communities.
ISIRV will continue to partner with BMGF to support delegates from low-and middle-income countries to attend

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
the Options Xll conference and other ISIRV meeting5, including RSV2025.
Future Plans
ISIRV activitles. collaborations and future strategy
The Society has a full calendar of events planned for the next 5 years, with the intention to move forward with
the development of ISIRV'S infrastructure to support excellent meetings and conferences.
th
5 Internatlonal Symposlum on Neglerted Influenza Vlruses
Ih
Durin8 8-10 April 2024. the 5 International Symposium on Neglected Influenza Viruses will take place In
Lexin8ton USA and include sesslons focused on Clinical and Experimental Vlrology, Emer8in8 Issues and New
Developments, Surveillance and Disease Investl8ation and Virus Transmission and Control. In view of ISIRWS
commitment to encouraging the attendance of early career scientists, early career researcher travel awards will
continue to be made available.
ISIRV Weblnar serfes
Buildin8 on the success of the webinars that have already taken place In 2024, several further webinars wlll take
place focused on "hot topics"
World Influenza Conference IWIC) 2024
The World Influenza Conference 2024, will be held in Boao, Hainan, China, in Julyi focused on"Inte8rated
Prevention and Control From Influenza to Respiratory Infectious diseases." The meeting will be jointly organised
by the Chinese Society for Preventative Medicine, Asia Pacific Alliance Combatin8 Influenza IAPACI), ESWI and
ISIRV The event will gather experts. to discuss global challen8es in respiratory disease prevention, vaccine
development, and internatlonal cooperation.
Optlons Xll
tions Xll in Brisbane, Australla wlll be held between 29 September-2 October 2024. The prestiglous event
will continue to build on the success of its predecessors with a 4-day format to deliver a strong scientific
programme with four parallel tracks, addressing a full range of 'real-world' issues relevant to the 'flu
communlty, plus additional spotlights on the latest research on SARS-CoV-2 and RSV.
Ih
Schools of Influenza
As part of Options Xll 2024, ISIRV wlll hold a one-day mini school of respiratory vlruses on 28 September, This
educatlonal event will be aimed at graduate students and young scientists who are starting. or in the early
stages of a career in influenza, public health, surveillance. research or product development and will provide
comprehensive preparatory background to maximise understanding at the conference as well as opportunity
for networking and meeting some of the Options invited speakers.
The Soclety has several collaborative partnerships whlch it intends to develop and enhance, in partlcular with
NGOS IWHOI and funders Includlng the Bill and Melinda Gates Foundation who are committed to support low-
and middle-income countries. and Flu Lab who funds and advances innovative solutions to influenza challenges.

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
Planning for a full School of Influenza at Qatar University is underway for January 2025.
13 International RSV Symposium (R5V2025)
This Symposium, taking place in 18uazu Falls, Brazil, 12 - 15 March 2025 will build on the success of RSV2022.
There will be the opportunity to submit abstracts for a number of oral presentations in each session as well as
poster presentations.
IMRP, Singapore 2025
We are excited to be hosting the 3, International Meeting on Respiratory Pathogens in Singapore in September
2025, targeted broadly at respiratory viruses with possible focus on diagnostics and genomics analysis.
Options Xlll Conference, Washington D.C.. USA
Plannin8 for the 2026 Options conference is underway and is set to take place in Washington D.C. in September.
Calls for interest in hosting Options 2028 and RSV 2029 will be made in early 2025.
Areas of focus
In addition to our events portfolio. plans are being made to strengthenlfocus on..
Further developing the operating infrastructure of ISIRV
Strengthening 8overnance arrangements, including the management of risk, creation and adoption of new
Articles of Association and terms of reference for SIGS, the Scientific Meetin8s Committee and newly-formed
Education Committee
Developing the ISIRV website, with a refresh of the Society's Vlsual identity accompanying the proposed
name change
Financial planning for planned expendlture and a review of the Society's investment policv
Succession planning for. and maximizing input from Council members
Increasing the global and career-stage diversity of Council
Forward planning for events in beyond 2025
Recruitment of a new Editor-in-chief for IORV & strengthening the link between the journal and societv
activities
Financial Revlew
th
This fiscal period began with the 7 AVG meeting in Seattle, In May 2023. The year proceeding was a
quieter year for the society in terms of events hosted, as it sat between years which host the ISIR V's
headline events. Nevertheless. the society was busy and focused on planning for the next events on the
th
horizon incuding the 5 NIV Symposium in Kentucky. USA. hosted in April 2024. as well as the next Options
conference in Brisbane. in September 2024.
Because the large biennial meetlngs Ioptlons and RSVI did not take place during the year, income from
charitable activities reduced in comparison to the previous year and totalled £225.362 [2023.. £1,743,712].
Thi5 income was largely was driven by conference registration fees and sponsorship income from the 7
AVG meeting. Membership income for the year was £14,96012023.' £111,308]. and this reductlon In fees
can be attributed to the year ended 31 March 2024 being a non-options year. ISIRV is committed to
developing its membership strategy to ensure there are clear membership benefits. The Council remains
committed to attracting new member5 to the Society and will continue to review membership benefits as
part of the Society's 5-year Strategic Plan.

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
Royalty receipts from operation of the IORVJournal increased during the period to £42.615. an increase of over
30% on the previous year12023: £32,601). The increase in royalties wa5 largely due to an ongoin8 rise in the
submission and acceptance of hi8h-quality general research.
The unrealised gain from investments of £16,55112023: £30,50410s5] help5 to fortify the Societrfs
investment balances and is reassuring in comparison with the devaluation in the previous year.
The reduction in income from registration fees as explained by FYE being a non-options and RSV meetin8 year
mean that the Society realised a financial deficit of £116,684 for the year. Thls deflcit was anticipated because
of ISIR V's ongoing commitment to SUPPOrting the delivery of its charitable activities. Despite the overall deficit
of £116.684 for the year, the Trustees are pleased to report that funds carried forward at the end of the period
remain healthy at £1,891,52312023.' £2,008,207].
Investments
The continuation of the war in Ukraine coupled with political tensions in the Middle East and other
reglons worldwide has resulted in market uncertainty. With Increases in inf lation, the economic backdrop
remains difficult, but Increasing interest rates has improved the prospect of investing in high-yield fixed
interest bonds. However, the Society recognises that the portfolio of stocks and shares are long term
investments and any short-term market volatility will be dampened by the longer term outlook.
The overall position is reviewed on a regular basis and the performance of individual shareholdings is
monitored, but a balanced view of the overall portfolio is taken and expectations of grovrth in the short-
term are modest.
For 2023124, dividend income is recorded as £24,89412023', £21,564). The portfollo of stocks and shares
was valued at £547,134 set against a cost of £673,775 and, as reported above. an unrealised gain of
£16,55112023: £30,50410551 has been recognised in these accounts.
Reserves Policy
The Society's designated reserves balance Is £675,000. This is the equivalent of at least 2 years, operatlng
expenditure and can be used to underwrlte the Soclevs flagshlp conference, OPTIONS for the Control of
Influenza, a meeting at the heart of the SocietTrls mi$5ion. The frequency of thi5 conference has been
changed from every three year5 to every two years. and this factor will challenge financial resources and
cashflow management significantly. The biennial conference life cycle of the OPTIONS meeting is planned
to be matched by the International RSV Symposium which has seen unprecedented growth in attendance.
The impact of these chan8es will be fully assessed at the annual review and it is anticipated that an
increase in the reserves balance will be required in the coming year to ensure sustainability.
Flnanclal Posltlon
Despite the challenges of recent years. the Society continue5 to grow in resilience. For this period, funds carried
forward are £1,891,52312023: £2,008,207]. This provides confidence in forward planning and exploring ways of
expanding the educational portfolio of the Society. Considerable investment has been made and will continue to
be made in ensuring the right talent, resources and infrastructure are secured to support the 50cieVs charitable
grovrth in the coming years.
Society reserves are strong and general funds will underwrite the ISIRV Programme 2025126, as we look forward
th
to an impressive line up of global events, which includes Options Xll (Brisbane, Australia), the 13 Internatlonal
10

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024
RSV Symposium Ilguazu Falls, Brazil), the International Meeting on Respiratory Pathogens (Singapore), Correlate5
of Protection Ivienna. Austrial, Neglected Influenza Virus Meeting (Cambodial, and Options Xlll (USA).
Going forward, the Trustees will remain vigilant to the change5 that can impact the work of the Society. The
ongolng Russia/Ukraine war and the unfolding crisis in the Middle East together with the economic conditions
of the global economy will continue to challenge both investments and event planning.
****

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
STATEMENT OF TRUSTEE'S RESPONSIBILITIES
The trustees (who are also directors of the International Society for Influenza and Other Respiratory Viru5
Diseases for the purposes of company law} are responsible for preparing the Trustees. Annual Report and
the financial statements in accordance with applicable law and United Kingdom Accounting Standards
(United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year, which 8ive a true
and fair view of the State of affairs of the charitable company and of the incoming resources and applicatlon
of resources. including the income and expenditure, of the charitable company for that period. In preparing
these financial statements. the trustees are required to:
select suitable accountln8 policles and then apply them consistently.
observe the methods and principles in the Charities SORP,.
makejudgements and estimates that are reasonable and prudent,.
state whether applicable UK Accounting Standards have been followed, subject to anv
material departure5 disc105ed and explained in the financial statements-
prepare the financial statements on the 8oin8 concern basis unless It is inappropriate to
presume that the charitable company will continue in operation.
The trustees are responsible for keeping adequate accounting records that disclose with reasonable
accuracy at any time the financial position of the charitable company and enable them to ensure that the
financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the
assets of the charitable company and hence for taking reasonable steps for the prevention and detection of
fraud and other irregularitie5.
Each of the trustees has confirmed that so far as they are aware, there is no relevant audit information las
defined by section 418 of the Companies Act) of which the charitable company's auditor is unaware and
that they have taken all the required steps as trustees to make themselves aware of any relevant audit
information and to establish that the auditor is aware of that information.
Audltor Appolntment
Following a review of our audit requirements. we have decided to seek a new auditor to support our
financial oversight. The process to identify and appoint a sultable firm is underway, and we will provide an
update once the appointment has been finalised. We thank our current auditors for their services and
commitment to ensuring accuracy and transparency in our financial reporting.
12

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
TRUSTEES. RESPONSIBILITIES STATEMENT
Small Companies Provision Statement
TheTrustees have taken advantage of the small companies, exemptions provided by sections 414B and
415A of the Companies Act 2006 from the requirement to prepare a strategic report and in preparing
the Trustees, report on the grounds that the charitable company is entitled to prepare its accounts for
the year in accordance with the small companies. regime.
The Trustees, Report was approved on 12 December 2024 and signed on their behalf by:
Professor Ultan Power. Treasurer and Trustee
13

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF INTERNATIONAL
SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
OPINION
We have audited the financial statements of the International Society for Influenza and Other
Respiratory Virus Oiseases I'the charitable companw) for the year ended 31 March 2024 which
comprise the Statement of Financial Activities. the Balance Sheet, the Statement of Cash Flows and
Notes to the financlal statements. Including significant accounting policies. The financial reporting
framework that ha5 been applied in their preparation is applicable law and United Kingdom Accounting
Standards. including Financial Reporting Standard 102 The Financial Reporting Standard applicable in
the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
8ive a true and fair view of the state of the charitable company's affairs as at 31 March 2024
and of its incomin8 resources and application of resources, includlng its income and
expenditure, for the year then ended:
have been properly prepared in accordance with United Kingdom Generally Accepted
Accounting Practice,. and
have been prepared in accordance with the requlrements of the Charlties Act 2011.
BASIS FOR OPINION
We conducted our audit in accordance with International Standards on Auditing IUK) IISAS IUKII and
applicable law. Our responsibilities under those standards are further described in the Auditor's
responsibilities for the audit of the financial statements section of our report. We are independent of
the charitable company in accordance with the ethical requirements that are relevant to our audit of
the financial statements in the UK. includlng the FRC'S Ethical Standard, and we have fulf illed our other
ethical re5ponsibilitles in accordance with these requirements. We believe that the audlt evidence we
have obtained is sufficient and appropriate to provide a basis for our opinion.
CONCLUSIONS RELATING TO GOING CONCERN
In auditing the financial statements, we have concluded that the trustees, use of the going concern
basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identlfied any material uncertainties relating to
events or conditions that, individually or collectively, may cast significant doubt on the charitable
company's ability to continue as a going concern for a period of at least twelve months from when the
financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors With respect to 80ing concern are
described in the relevant sections of this report.
OTHER INFORMATION
The other information comprises the information included in the annual report, other than the
financial statements and our auditorfs report thereon. The trustees are responsible for the other
information. Our opinion on the financial statements does not cover the other information and we do
not express any form of assurance conclusion thereon.
14

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF INTERNATIONAL
SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
In connection with our audit of the financial statements, our responsibility is to read the other
information and. in doing so. consider whether the other information is materially inconsistent with
the financial statements or our knowledge obtained in the audlt or otherwise appear5 to be materlally
misstated. If we identify such material inconsistencies or apparent material misstatements, we are
required to determine whether there is a material misstatement in the financial statements or a
material misstatement of the other information. If, based on the work we have performed, we
conclude that there is a material misstatement of this other information. we are required to report
that fact.
We have nothing to report in this regard.
mA￿ERs ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION
We have nothing to report in respect of the following matters in relation to which the Charities
{Accounts and Reports) Regulations 2008 require us to report to you if, in our oplnion.,
the information given in the Trustees, Report is inconsistent in any material respect with the
financial statements; or
sufficient accounting records have not been kept,. or
the financial statements are not in agreement with the accounting records: or
we have not received all the information and explanations we require for our audit.
RESPONSIBILITIES OF THE TRUSTEES
As explalned more fully in the Statement of Trustees, Responsibilltles (set out on page 121, the trustees
(who are also the directors of the charitable company for the purposes of company lawl are
responslble for the preparatlon of the flnancial statements and for being satisfied that they give a true
and fair view. and for such internal control as the trustees determine is necessary to enable the
preparation of financial statements that are free from material misstatement, whether due to fraud or
error,
In preparing the financial statements, the trustees are responsible for assessing the charitable
companvs ability to continue as a going concern, disclosingi as applicable. matters related to goin8
concern and using the golng concern basis of accounting unless the trustees either intend to liquidate
the charitable company or to cease operation5. or have no realistic alternative but to do so.
AUDITOR'S RESPONSIBIUTIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS
We have been appointed as auditor under section 144 of the Charities Act 2011 and report in
accordance with the Act and relevant regulations made or having effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole
are free from material misstatement, whether due to fraud or error, and to issue an auditor's report
that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that
an audit conducted in accordance with ISAS IUKI will always detect a material misstatement when it
exists. Misstatements can arise from fraud or error and are considered material if, individually or in
the aggregate, they could reasonably be expected to influence the economic decisions of users taken
on the basis of these financial statements.
15

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF INTERNATIONAL
SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
Irregularities, includlng fraud. are instances of non-compliance with laws and regulations. We design
procedures in line wlth our responsibilities, outlined above, to detect material misstatements in
respect of irregularities, including fraud. The extent to which our procedures are capable of detecting
irregularities, including fraud is detailed below:
EXTENT TO WHICH THE AUDIT WAS CONSIDERED CAPABLE OF DETECTING IRREGULARITIES,
INCLUDING FRAUD
Our approach to Identlfying and assessing the risks of materlal misstatement in respect of
Irre8ularities, including fraud and non-compliance with laws and regulations, was as follows:
the engagement partner ensured that the engagement team collectively had the appropriate
competence, capabilities and skills to identify or recognise non-compliance with applicable
laws and regulations,.
we assessed the extent of compliance with the laws and re8ulations identifled above through
making enquiries of management and inspectin8 le8al correspondence; and
• we identified laws and re8ulatlons which were communicated within the audit team regularly
and the team remained alert to instances of non-compliance throughout the audit.
We considered the nature of the charitable company's sector and its control environment, and
reviewed the charitable companvs documentation of their policies and procedures relating to fraud
and compliance with laws and regulations. We also identified the laws and regulations applicable to
the charitable company through discusslons With the Trustees and other management, and from our
cumulative audit, knowledge and experience of the charitable company.
We obtained an understanding of the legal and regulatory framework that the Charitable company
operates in, and identified the key laws and regulations that:
had a direct effect on the determination of material amounts and disclosures in the financial
statements. These included the Companies Act 2006, the Charities Act 2011, the Charities
SORP, and UK financial reporting standards a5 Issued by the Financial Reporting Council,. and
do not have a direct effect on the financial statements but compliance with which may be
fundamental to the Charitable company's ability to operate or to avoid a material penaltv.
These included the Charitable companvs regulatory requirements, employment and taxation
legislations, the Data Protection Act and the Bribery Act.
We assessed the susceptibility of the charitable compan¢s financial statements to material misstatement,
including obtaining an understanding of how fraud might occur, by..
making enquiries of management as to where they considered there was
susceptibility to fraud, their knowled8e of actual, suspected and alleged fraud; and
• considering the internal controls and policies in place to mitigate risks of fraud and non-
compliance with laws and regulations.
16

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF INTERNATIONAL
SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
In response to the risk of irregularities and non-compliance with laws and regulations, we designed
procedures which included, but were not limited to:
• reviewing financial statement disclosures by testing to supporting documentation to assess
compllance with provisions of relevant laws and regulations described as having a dlrect effect
on the financial statements;
performing analytical procedures to identify any unusual or unexpected relationships that mav
indicate risks of material misstatement due to fraud;
• enquiring of the Trustee concerning actual and potential litigation and clairns, and instances of
non-compliance with laws and regulations: and
• reading minutes of Trustee meeting5, reviewing internal audit reports and reviewing
correspondence with the Charities Commission.
There are inherent limitations in our audit procedures described above. The more removed that laws
and regulations are from financial transactlons, the less likely it is that we would become aware of non-
compliance. Auditing standards also limlt the audit procedures required to identify non-compliance
with laws and regulations to enquiry of the Trustees and other management and the inspection of
regulatory and legal correspondence, if any.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have
detected some material misstatements in the financial statements, even though we have properly
planned and performed our audit in accordance with auditing standards. For example, the further
removed non-compliance with laws and regulations {irregularitiesl is from the events and transaction5
reflected in the financial statements, the less likely the inherently limited procedures required by
audltlng standards would identify It. In addition, as with any audlt, there remained a higher risk of non-
detection of Irregularities, as these may involve collusion, forgery, intention31 omissions,
misrepresentations, or the overrlde of Internal controls. We are not responsible for preventing non-
compliance and cannot be expected to detect non-compliance with all laws and regulations.
A further descrlptlon of our responsibilities is available on the Financial Reporting Councll's webslte
at- www.frc.org.uk/auditor5responsibilities. Thi5 description forms part of our auditorfs report.
17

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF INTERNATIONAL
SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS DISEASES
USE OF OUR REPORT
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4
of the Charities (Accounts and Records) Regulations 2008. Our audit work has been undertaken so that
we might state to the charitable company's trustees those matters we are required to state to them in
an auditors, report and for no other purpose. To the fullest extent permitted by law. we do not accept
or assume responsibility to anyone other than the charitable company and the charitable company's
trustees as a body. for our audit work, for this report, or for the opinions we have formed.
SHAW GIBBS (AUDITI LIMITED
Statutory Auditor
Salatin House
19 Cedar Road
Sutton, Surrey
SM2 SDA
Date:
Shaw Gibbs (Audit) Limited is eligible for appointment as auditor of the charity by virtue of its eligiblllty
for appointment as audltor of a company under sectlon 1212 of the Companles Act 2006.
18

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
STATEMENT OF FINANCIAL ACTIVITIES
(INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2024)
Unrestricted
Funds
Restricted
Funds
Notes
2024
2023
Income Irom:
Charitable activities
Investments
225,362
29,561
215.362 1,743,712
29.561
23,621
Total income
2S4,923
254.923 1,767,333
Empendlture on:
Charltable actlvltles
Support and Governance
212,933
175,225
212,933
175,225
883,835
121,020
Total expendSture
388,158
388,158 1,004,855
Net galnllloss) on Investments
li
16,551
16,551
130,504)
Net (deftdtl/surplus
{116,6841
(116,6841
731,974
Transfers between funds
Net movement In funds
1116,6841
(116,6841
731,974
Re¢onclllatlon of Funds:
Total funds brought forward
1,907,887 100,320 2,008,107 1,276,233
Total funds ¢arrled forward
1.791,203 100.320
1,891,523 2,(X)8,207
All of the results derive from continuing activities.
The Statement of Financlal Activitles Includes all gains and10sses recogni5ed in the year.
The notes on pa8es 22 to 30 form part of the financial statements.
19

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
BALANCE SHEET AS AT 31 MARCH 2024
(COMPANY REGISTRATION NUMBER 06021083)
Notes
2024
2023
Cuirent a55ets
Debtors
Current asset investments
Cash at bank and in hand
io
li
19,320
554,749
1,460,113
151,698
494,254
1,545,056
2,034,183
2,191,008
Creditors: amounts falling due wlthin one year
12
1142,6591
(182,8011
Net ¢urrent assets
1,891,523
2,IJ08,207
Total assets less current Ilabllitles
1,891,523
2.008,207
Funds
Restricted funds
Oesi8nated funds
General fsjnds
13
14
14
100,320
675,000
1,116.203
100,320
717,557
1,190,330
Total lunds Carrled forward
1,891,523
2,008,207
These financial statements have been prepared in accordance with the special provisions relating to small
companies within Part 15 of the Companies Act 2006 and the Financial Reporting Standard applicable in the UK and
Republic of Ireland (Charitles SORP {FRS 10211 and constitute the annual accounts requlred by the Companles Act
2006 and are for the Circulation to members of the charitable company.
The trustees are satisfied that the charitable company was entitled to exernption from audit for the year ending 31
March 2024 under section 477 of the Companies Act 2006 and the trustees have not requested an audit in
accordance with section 476 of the same act. However, an audit is required in accordance with section 144 of the
Charities Act 2011.
The trustees. who are regarded directors for the purpose of the Companies Act 2006, acknowledge their
responsibilities for complying With the requlrements of the Act with respect to accounting records and the
preparation of accounts.
The accounts were approved and authorised for issue bythe Trustees on 12 December
2024 and 518ned on their behalf by..
Profe$50r Ultan Power- Trustee and Dlrertor. Treasurer of ISIRV
The notes on pages 22 to 30 form part of the finèncial statements.
20

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2024
Notes
2024
2023
Net ¢ash used in operatin8 artivities
17
(65,894)
721,972
Cash flows from Investment artlvltles;
Dividends and interest received from investments
Proceeds from sale of investments
Purchase of investments
Cash used in Investing artlvitles
24,894
23,621
22.933
li
IDecrea5e)lincrease in cash and cash equlvalents
(89,219)
753,474
Cash and cash equivalents at beginning of year
1.556,946
803,472
Total cash and cash equlvalents at end of year
Cash and cash equivalents beln8:
Cash at bank and in hand
Liquid resources held in current asset investments
1.460.113
1,545,056
li
Cash used In Investing actlvltles
The notes on pa8es 22 to 30 form part of the financial statements.
21

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
ACCOUNTING POLICIES
The principal accounting policies are set out below. The accounting policies have been adopted conslstently in all
the years presented, unless Otherwise stated.
Going concern
Having considered a period of more than 12 months from the signing of these financial statements. the trustees
assessment is that the charitable company Is a 8oln8 concern and these accounts have therefore been prepared
on a goin8 concern ba51S.
Basls of aecountlng
The financial statements have been prepared in accordance wlth Accounting and Reporting by Charities: Statement
of Recommended Practlce applicable to charities preparlng their accounts in accordance with the Flnanclal Reportlng
Standard applicable in the UK and Republic of Ireland- (Charites SORP IFRS 10211, the Financial Reportin8 Standard
applicable in the UK and Republic of Ireland IFRS 1021. the Charities Act 2011 and the Companie5 Act 2006.
International Society for Influenza and Other Respiratory Virus Diseases meets the definition of a public benefit
entity under FRS 102.
These flnancial statement5 have been prepared usin8 the hlstorical cost conventlon except that as dlsclosed in the
accountin8 pollcles certaln items are shown at fair value.
The functional currency of the charitable company is considered to be pounds sterling {£) because that is the
currency of the primary economic environment in whlch the charitable company operates. The financial statements
are presented in pounds sterlin81£1.
Judgements and key sources of estlmatlon uncertalnty
In the opinion of the trustees there are no judgements or key sources of estimation uncertainty which could
materially affect the financial statements.
Income
The principal policies on income are as follows:
Donotions- Donations are credited in the year in which they are received.
Grant income - Grant income Is generally related to specific conferences and. where thls Is the case, Is
reco8nised In the period in whlch the conference is run in line with grant terms and matched expenditure.
Unspent grants are returned or repurposed in Ilne with grant terms.
Membership income
Direct membership income is recognised when received. Membership is also
included as part of conference attendance fees paid by non-members. Since the amounts are not
refundable. they are recognised in the year they are received.
22

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
ACCOUNTING POLICIES
Conference ottendonce and sponsorship
Attendance fees and sponsorship income are
recognised in the period in which the conference is run.
Investment income- Interest and dividends are recognised in the perlod in which they are
receivable.
Expendlture
Expenditure on charitable activities includes:
Conference c05ts- those incurred in organising and running medlcal conferences and accounted for in the
period in which the conference is run.
School of Respirotory Viruses costs - those incurred in relation to the ongoing activity of or8anisin8 and
running a school providing specialised training on influenla and other respiratory virus diseases and
accounted for in the period to whlch they relate.
Governonce costs
those Incurred In the governance of the charltable companvs assets, primarily
associated with constitutional and statutory requirements and accounted for in the period to which they
relate.
Support C05t5
those incurred on central functions. allocated to activity cost categories on a basis
consistent with the use of resources and accounted for in the period to which they relate. Support costs
include consultancy cost5, general office costs and bank charges.
Irrecoverable VAT Is charged as a cost against the activity for vthich the expenditure was incurred.
Fund strurture
The fund5 held by the charitable company are elther..
Generalfunds- these are unrestrlcted funds which can be used in accordance with the charltable objects at
the discretion of the trustees and include des18nated funds.
Designated Junds - form pèrt ot the unrestricted funds and represent funds embarked by the trustees for
specific future project5 or purpose.
Restrictedfund5- these are funds that can only be used for partltular restricted purposes within the objects
of the charitable company. Restrictions arise when specified by the donor or when funds are raised for
partlcular purposes.
Oebtors
Oebtors are recognised initially at the transaction price. They are subsequently measured at amortised cost, less
provision for impairment. A provision for the impairment of debtors is established when there is objective evidence
that the charitable company will not be able to collect all the amounts due according to the original terms of the
debt.
23

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
ACCOUNTING POLICIES
Prepaid expenditure and accrued income is valued at the amount prepaid or accrued and calculated in line with
the charitable companvs stated policies on expendilure and income.
Current Asset Investments
Current asset investments are recognised initially at the transaction pri¢e and subsequently measured at the
market value. Gains and losses on current asset investments are recognlsed in the Statement of Financial Activitles.
Cash and cash equlvalents
Cash and cash equivalents comprise cash at bank and In hand as disclosed In the balance sheet and liquid resources
included in current asset investments held by Investment managers as part of the normal course of managing the
charitable companvs investments.
Credltors
Creditors are recognised where the charitable company has a present obligation resulting from a past event that will
probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured
or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for
any trade discounts due.
Accrued expenditure and deferred income Is valued at the amount accrued or deferred and calculated In Ilne wlth
the charitable company's stated policies on expendlture and income.
Flnanclal Instruments
The charitable Company only has financial assets and financial liabilities of a kind that qualify as basic financial
instruments. 8asic financial instruments are initially recognised at transaction value and subsequently measured at
their settlement value.
2 Legal status of the charlty
The charltable company is a company limited by guarantee and has no share capital. The Ilability of each member In
the event of a winding up is limited to £10.
3 Taxation
The charitable company is exempt from tax on income and 8ains falllng wSthin section 505 of the Taxes Act 1988 or
section 256 of the Taxation of Char8eable Gains Act 1992 to the extent that these are applied to its charitable objects.
No tax charges hève arisen in the charity.
Related party transactlons
Details of Trustees and key management personnel emoluments and expenses are disclosed in note 9. There were
no outstanding balances with related parties as at 31 March 202412023: Nill.
24

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Net incomellexpenditure) forthe year
2024
2023
Thls 55 Stated after char8ln8'.
Auditors remuneration..
Audit of these financial statements
Other financial servlces provlded by the auditor
3,9CQ
1,620
Incomefrom charitable activities
Year ended 31 March 2024
Unrestricted
Funds
Restricted
Funds
2024
Membership subscriptions
Royalties
Conference attendance fees
Conference sponsorship and grants
14,960
42,615
89,589
78,198
14,960
42,615
89,589
78,198
225,362
225,362
Year ended 31 March 2023
Unrestricted
Funds
Restricted
Funds
2023
Membership subscriptions
Royaltles
Conference attendance Fee5
Conference sponsorship
Grants
111,308
32,601
876,827
400,867
322,109
111,308
32,601
876,827
400,867
322,109
1,743,712
1,743,712
7 Expendlture on tharitable activities
Year ended 31 March 2024
Unrestricred
Funds
Restricted
24
Conferences
Web51te costs
Gain on foreign exchange
197.405
15,273
255
197A05
15,273
255
212, 933
212,933
25

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Expenditure on charitsble artivities {continued)
Year ended 31 March 2023
Unrestricted
Restricted
Fund5
Conferences
Website costs
Gain on foreign exchange
&85,533
14,103
115,8011
88S,533
14.103
(15.801)
883,835
883,835
8 Support and governance
Year ended 31 March 2024
Support Governance
8asls of
Apportlonrn•nt
Consultancyfees
General office costs
Bank char8es
Accounlancy services
Audit fees
ISIRV strate￿ Day
96,940
14,827
1.063
34,723
131,663
14,827
1,063
Time Ihoursl
Time Ihoursl
Support
Governance
Governance
4,800
4,800
22,872
135.702
39,523
175.225
Year ended 31 March 2023
Support Governance
Costs
Costs
Basls of
Total Apportlonment
ConsuStancyfees
General office costs
Bank charges
Independent Examination
Audit fees
75,234
14.290
718
25,078
100,312 Time Ihoursl
14,290 Time Ihoursl
718
Support
1,800 Governance
3.900 Governance
1,800
3,900
90.242
30,778
121,020
26

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
Staff costs, trustee remuneration and expense5 and key managernent personnel
The charltable company had no employees during the year12023'. no employee51.
No trustees or persons connected with them received any emoluments in their role as trustees from
the charitable company. No trustee received reimbursement of expenses12023- £nlll incurred in carrying
out their duties.
10 Oebtors
Prepayments and accrued income
19,320
151,698
11 Current Ass•1 Investments
2024
2023
Listed investments..
Carrying value (market value) at l April
Additions to investments at cost
Oisposals at carrying value
Gain on disposal of investments
Gainlllossl on revaluation
482,364
48,219
510,749
15,052
(22,933)
3,749
134,253)
16,551
Carrying value (market value) at 31 March
547,134
482,364
Liquid resources
7,615
11,890
Total Current asset investments at 31 March
554,749
494.254
Historical cost at 31 March 2024 was £673,77512023: £628.6641.
27

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
12 Credltors: amounts falllng due wlthln one year
2024
2023
Accrued expenditure
Deferred income
109,216
33,443
126.036
56.765
142,659
182,801
Deferred Income comprises grants and conference attendance fees relating to conference5 to be held in a
subsequent accounting perlod.
13 Restrlrted fund5
Transler
be￿een
fvnds
Balance at
IApr23
Balance at
31 Mar 24
Year ended 31 March 2024
Income
Expendlture
Restricted 8rants and
le8acies'.
G.C,Schlld Fund
l(X).320
100,320
IW.320
100,320
Transfer
between
funds
Balance at I
Balance at 31
Year ended 31 March 2023
Apr 22
Income
Expenditure
Mar 23
Restrlcted grants and legacles:
G.C.Schild Fund
10).006
314
100,320
ItK),006
314
100,320
Restricted funds represent the balance on G Schild legacy received in 2020. The legacy will be used to fund two
pre5ti8lOUs ISIRV Awards- The Geoffrey Schild Lecture Award and The Geoffrey Schild Award.
28

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
14 Unrestrlcted lunds
Year ended 31 Marth 2024
Transfer
between
funds
Balance at I
Apr 23
Gain on
Investments
Balance at
31 Mar 24
Income
Expendlture
Designated funds..
DesignatedreseThes
fund
Lors Hooheim Fund
ISIRVEducation Fund
General funds
675,OCX)
24,912
17.645
1,190,330
675,000
24,912
17,645
1,073.646
254.923
1388,1581
16,551
Total
1,907,887
254.923
1388,1581
16,551
1,791,203
Year ended 31 March 2023
Transfer
between
funds
Bal•nceat I
Apr 22
L￿On
Investments
Balance at
31 Mar23
In¢ome
Expendilure
Designated funds:
Designatedre5erves
fund
Lor5 Ht70heim Fund
ISIRV Education Fund
General funds
675,000
24,912
17.645
4S8.670
675,000
24,911
17.645
1,190,330
1.767,019
(l.1))4,8551
{30,5041
Total
1,176,227
1.767,019
[1,￿,855)
130,5041
1,907,887
Name of lund
Descii
tlon nature and
oses of the fund
Designated reseThies fund
Unrestricted funds earmarked for specified use.
Lars Haaheim fund
Initially established as a restricted fund with a donation from
Vigdis Haaheim, widow of Lars Haaheim. a founder of the School of
Influenza for the education and ongoing development of young
Scientists.
ISIRV Education Fund
A general fund to support the development of awards for early
career researchers.
29

INTERNATIONAL SOCIETY FOR INFLUENZA AND OTHER RESPIRATORY VIRUS
DISEASES
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
IS Anjlysls of net assets between funds
Year ended 31 March 2024
Unrestiicted
fund
Restricled
fund
Total
Current assets
Current liabillties
1,933,862
1142,659)
100,320
2,034,182
{142,6591
1,791,203
100,320
1,891,523
Year ended 31 March 2023
Unrestrlcted
Restrlcled
fund
Total
Current assets
Current liabilities
2,090,688
1182,8011
100,320
1,191,008
1182,8011
1,907,887
100,320
2,008,207
16 Transfers between fvnds
At 31 March 2024 no funds were transferred from restricted funds to unrestricted funds
12023.. £01.
17 Reconciliation of net Income to net cash flow from operatlng artmtles
2024
2023
Net movement in funds
Adju5tmentfvr.'
IGain)/loss on investments
Deduct income from investments
Decreasellincreasel in debtors
Increaselldecreasel in creditors
{116.6841
731.974
116,5511
124,8941
132.377
140.1421
30.504
123,6211
171.3141
54.429
165,8941
721.971
30